Consumers and life science startup companies alike are reacting strongly to the recent decision by the FDA to restrict the genetic testing company, 23andMe, from marketing its genetic testing service. In our day-to-day work, we are frequently approached with a gamut of regulatory questions from both large and small life science companies navigating the intersection … Continue reading “There May Be More to the FDA/23andMe Story Than Meets the Eye”
Author: Joanne Gibbons
Joanne Gibbons is a senior consultant and Emily Welsch is a consultant at Halloran Consulting Group, a specialty consulting firm to life science companies focusing on clinical, regulatory and quality.